COAG (Hemab Therapeutics Holdings) Interest Expense: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $46.54
! 2 Warning Signs
View Full Analysis

What is Hemab Therapeutics Holdings Interest Expense?

Hemab Therapeutics Holdings COAG +3.48% 11 Interest Expense is $ Mil as of Dec. 2025. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Hemab Therapeutics Holdings's interest expense for the six months ended in Dec. 2025 was $ 0.00 Mil. Hemab Therapeutics Holdings does not have enough years/quarters to calculate its interest expense for the trailing twelve months (TTM) ended in Dec. 2025.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Hemab Therapeutics Holdings's Operating Income for the six months ended in Dec. 2025 was $ -70.12 Mil. Hemab Therapeutics Holdings's Interest Expense for the six months ended in Dec. 2025 was $ 0.00 Mil. GuruFocus does not calculate Hemab Therapeutics Holdings's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hemab Therapeutics Holdings  (NAS:COAG) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hemab Therapeutics Holdings's Interest Expense for the six months ended in Dec. 2025 was $0.00 Mil. Its Operating Income for the six months ended in Dec. 2025 was $-70.12 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was $0.57 Mil.

Hemab Therapeutics Holdings's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

GuruFocus does not calculate Hemab Therapeutics Holdings's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Hemab Therapeutics Holdings Inc has enough cash to cover all of its debt. Its financial situation is stable.

Hemab Therapeutics Holdings Interest Expense Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Interest Expense Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
Interest Expense
0.00 0.00

Hemab Therapeutics Holdings Semi-Annual Data
Dec24 Dec25
Interest Expense 0.00 0.00
COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $ Mil mean?
Hemab Therapeutics Holdings (COAG) has a Interest Expense of $ Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Hemab Therapeutics Holdings and its competitors.
Is Hemab Therapeutics Holdings' Interest Expense too high?
Hemab Therapeutics Holdings' current Interest Expense is $ Mil. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Interest Expense compare to ZLAB and SLS?
Hemab Therapeutics Holdings' Interest Expense of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Hemab Therapeutics Holdings and its competitors. Hemab Therapeutics Holdings's current Interest Expense is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Interest Expense of $ Mil. The current Interest Expense is $ Mil. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Interest Expense is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.54
Price